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Abstract
Background: Many gene-set analysis methods have been previously proposed and compared through simulation
studies and analysis of real datasets for binary phenotypes. We focused on the survival phenotype and compared
the performances of Gene Set Enrichment Analysis (GSEA), Global Test (GT), Wald-type Test (WT) and Global Boost
Test (GBST) methods in a simulation study and on two ovarian cancer data sets. We considered two versions of
GSEA by allowing different weights: GSEA1 uses equal weights, yielding results similar to the Kolmogorov-Smirnov
test; while GSEA2’s weights are based on the correlation between genes and the phenotype.
Results: We compared GSEA1, GSEA2, GT, WT and GBST in a simulation study with various settings for the
correlation structure of the genes and the association parameter between the survival outcome and the genes.
Simulation results indicated that GT, WT and GBST consistently have higher power than GSEA1 and GSEA2 across
all scenarios. However, the power of the five tests depends on the combination of correlation structure and
association parameter. For the ovarian cancer data set, using the FDR threshold of q < 0.1, the GT, WT and GBST
detected 12, 6 and 8 significant pathways, respectively, whereas neither GSEA1 nor GSEA2 detected any significant
pathways. In addition, among the pathways found significant by GT, WT, and GBST, three pathways - Purine
metabolism, Leukocyte transendothelial migration and Jak-STAT signaling pathway - overlapped with those
reported in previous ovarian cancer microarray studies.
Conclusion: Simulation studies and a real data example indicate that GT, WT and GBST tend to have high power,
whereas GSEA1 and GSEA2 have lower power. We also found that the power of the five tests is much higher
when genes are correlated than when genes are independent, when survival is positively associated with genes. It
seems that there is a synergistic effect in detecting significant gene sets when significant genes have within-class
correlation and the association between survival and genes is positive or negative (i.e., one-direction correlation).
Background
Gene-set analysis is a microarray data analysis method
that uses existing knowledge of biological pathways, or
sets of individual genes that are linked via related biolo-
gical functions. Gene-set analysis mainly aims to dis-
cover gene sets for which expression is associated with a
phenotype of interest. Compared to single-gene analyses,
gene-set analyses may lead to more interpretable results
by yielding insights into biological mechanisms.
Furthermore, considering gene sets rather than single
genes can reduce problems associated with multiple
testing, since there are typically far fewer gene pathways
than individual genes. Initially, gene-set analyses focused
on identifying biological pathways (i.e., sets of genes)
that are differentially expressed between two classes of a
phenotype such as tumor vs. normal cells. Mootha et al.
[1] proposed Gene Set Enrichment Analysis (GSEA),
based on the Kolmogorov-Smirnov statistic, which mea-
sures the maximum degree of differential gene expres-
sion in a gene set across a binary phenotype.
Subramanian et al. [2] improved GSEA by weighting
each gene according to its correlation with the pheno-
type, and calculating a running-sum statistic; in contrast,
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correlation between genes and the phenotype. GSEA
calculates a p-value by permuting the original data set,
which is computationally intensive for a large dataset.
Kim and Volsky [3] proposed a parametric analysis of
gene-set enrichment, which calculates a Z-score for a
given gene set from a parameter such as fold change
value between two classes of a phenotype, and makes
statistical inference from the asymptotic normal distri-
bution of the Z score. Dinu et al. [4] described some cri-
tical problems with GSEA, and proposed an alternative
method by extending an individual gene analysis
method, Significance Analysis of Microarrays, to gene-
set analysis (SAM-GS). In addition, they compared
SAM-GS to GSEA using a mouse microarray dataset
with simulated gene sets, and showed an advantage to
SAM-GS over GSEA in the analysis of three real micro-
array datasets.
Recently, gene-set analysis methods have been
expanded to include other kinds of phenotypes, such as
censored survival time and quantitative traits. Goeman
et al. [5] proposed the Global Test, a score statistic
based on random-effects modeling of parameters corre-
sponding to the coefficients of the individual genes in
the pathway. Goeman et al. [6] extended the Global
Test to assess association of a set of genes with survival
time based on a Cox proportional hazards model. In
addition, Binder and Schumacher [7] considered fitting
high-dimensional survival models while allowing for
mandatory clinical covariates using a boosting algo-
rithm. Boulesteix and Hothorn [8] instead proposed the
Global Boost Test, which combines a Cox model for
modeling the clinical covariates with a boosting algo-
rithm for modeling the additional predictive value of
high-dimensional gene expression data. Furthermore,
Adewale et al. [9] proposed a unified general analysis
method for microarray data for identifying pathways
whose expression is associated with a phenotype of any
kind, adjusting for covariates that may also be associated
with the phenotype of interest. This unified pathway
analysis method combines the regression-based test sta-
tistic for each individual gene in a pathway of interest
into a real pathway-level test statistic. The form of the
test statistic is a sum of squares of the Wald statistic for
individual genes in the pathway of interest.
Gene expression profiles have been used extensively in
the prediction of tumor subtypes or patient survival
(Alizadeh et al. [10], Golub et al. [11], and Rosenwald et
al. [12]). Initially, many studies focused on expression
levels of single genes to predict tumor subtype or
patient survival. Among many thousands of microarray
measurements, each relating to the expression level of a
single gene, a subset of significant genes can be identi-
fied by constructing a prediction model using the lasso
(Gui and Li [13], Tibshirani [14]), principal components
analysis (Tian et al. [15]), supervised principal compo-
nent analysis (Bair and Tibshirani [16]), support vector
machines (Furey et al. [17]), and other methods. How-
ever, single genes are often not of primary interest
because the activities of entire pathways or genomic
regions that are suspected to be more biologically rele-
vant. In addition, combining gene expression data with
prior biological knowledge of groups of genes improves
prediction accuracy and interpretability of survival mod-
els. The prediction of patient survival may be improved
by integrating gene expression data with prior biological
knowledge such as gene sets and pathways, as well as by
adjusting for covariates such as age, sex, and other clini-
cal variables. Chen and Wang [18] proposed a general
strategy for improving prediction accuracy and inter-
pretability by constructing pathway-based prediction
models for survival, which outperform the prediction
models based on expression levels of single genes.
Recently, Liu et al. [19] compared the statistical
performance of three gene-set analysis methods - the
Global Test, ANCOVA Global Test, and SAM-GS - for
a binary phenotype based on simulated data and real
microarray datasets. They reported similar performances
for all three methods after appropriate standardization,
given the use of permutation-based inference. They also
showed the advantage of the Global Test and ANCOVA
Global Test, which are able to analyze survival pheno-
types and adjust for covariates. To our knowledge, how-
ever, the performances of gene-set analysis methods
with a survival phenotype have rarely been studied via
simulation. In this paper, we compare the performances
of five gene-set analysis tests: two different GSEA tests
(GSEA1 and GSEA2) [1,2], Global Test (GT) [6], Wald-
t y p eT e s t( W T )[ 9 ]a n dG l o b a lB o o s tT e s t( G B S T )[ 8 ]
for assessing differential expression associated with the
survival phenotype based on a simulation dataset and a
real dataset of ovarian cancer patients.
Results
Simulation experiment
We generated a simulation dataset by the following
procedure to evaluate the performance of five gene-set
analysis tests:
(i) We randomly generated observations from a
multivariate normal with a zero-mean vector and a
variance-covariance matrix ∑, denoted by MVN(0,∑).
(ii) We randomly generated a vector of regression
coefficients, b, from either a uniform distribution or
a normal distribution. This represents the associa-
tion between survival and gene expression.
(iii) Using the observations generated in (i) and the
vector of regression coefficients b generated in
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Page 2 of 10(ii), we constructed a survival time from a Cox
model with a specified baseline hazard function.
Censoring times were generated from an exponential
distribution with a parameter l. The parameter l
was determined by the censoring fraction.
In the simulation study, we considered various para-
meters: the total number of genes (p), the sample size
(n), the fraction of censoring (cp), the size of a gene set
of interest (m), and the proportion of significant genes
in the gene set (mp). To check the size of the five tests,
we randomly generated gene expression variables from
MVN(0,∑), ∑ =0 . 2 Ip,w h e r eIp is an identity matrix of
dimension p × p, and constructed survival times from a
Cox model with bj =0 ,j = 1,..., p and the constant base-
line hazard rate of 0.005.
For the power calculation, we also randomly generated
gene expression variables from MVN(0,∑) and con-
structed survival times from a Cox model with the para-
meter b and the baseline hazard function has an
exponential distribution with the hazard rate of 0.005.
Here ∑ and b were specified according to the following
scenarios. First, we considered four different correlation
structures of gene expression variables as implemented
i nL i ue ta l .[ 1 9 ]a n dJ u n ge ta l .[ 2 0 ] .C a s e( I )i st h a ta l l
gene expressions are independent, which assumes the
correlation matrix as ∑ =( sij) with sii = 0.2 for i = 1,..., p;
sij = 0 for i ≠ j, with i, j = 1,..., p. Case (II) is that only sig-
nificant genes are correlated within a gene set but non-
significant genes are independent, that is, ∑ =( sij)w i t h
sii =0 . 2f o ri = 1,..., p; sij = 0.02 if two significant genes
fall into the same gene set and sij =0o t h e r w i s e .C a s e
(III) is that there is an autoregressive correlation between
significant genes, that is, ∑ =( sij)w i t hsii =0 . 2f o ri =
1,..., p; sij = 0.2 × 0.1
|i-j| if two significant genes fall into
the same gene set and sij = 0 otherwise. Case (IV) is that
there is an unstructured correlation between significant
genes, that is, ∑ =( sij)w i t hsii =0 . 2f o ri = 1,..., p; sij =
0.2 × rij, if two significant genes fall into the same gene
set and sij = 0 otherwise, where rij is a random variable
generated from N(0,0.1
2). Secondly, we considered two
different ways of generating the regression coefficient, bj,
for j = 1,...,[m × mp], to investigate how the association of
survival with genes affects the power for detecting the
significant gene sets. Here [a]r e p r e s e n t st h eg r e a t e s t
integer less than or equal to a. Case (A) is that the survi-
val is positively associated with genes by generating only
positive coefficients from a uniform distribution U
(0.2,0.6). Case (B) is that survival is randomly associated
with genes by generating the coefficient from N(0,0.5
2).
For the rest of the regression coefficients, we set bj =0
for j =[ m × mp]+1,..., p.
To assess the size and power of the tests, we imple-
mented the simulation procedure as follows: (i) We
calculated the test statistic for each method, (ii) per-
muted the samples 1000 times, recalculated the test sta-
tistics, and used these permuted test statistics to
estimate the p-value, (iii) and then repeated procedures
(i) and (ii) 500 times to estimate the size and 200 times
to estimate the power, respectively. The size is estimated
as the observed proportion of replications with a p-value
smaller than the nominal size a = 0.05, and the power is
estimated as the observed proportion of replications of
in which the null hypothesis was correctly rejected at
the nominal size a = 0.05.
Table 1 shows the sizes of the five tests for p =2 0 0
with n = 50,80, m = 20,50, and cp = 0.0,0.1,0.3,0.5. As
shown in Table 1, the empirical sizes of the five tests
are well controlled across all possible combinations of
parameters. Table 2 displays the power of the five tests
for p=200, n = 80, m = 50 under the combinations of
cp = 0.0,0.3 and mp =0.1,0.3,0.5 across all possible sce-
narios of gene correlation structure, and all scenarios of
the association parameter.
The results of Tables 1 and 2 are depicted in Figures 1
and 2 under the censoring fractions of cp = 0.0 and 0.3,
respectively. In each plot, the ten different lines repre-
sent the power of the five tests under the two different
scenarios of cases (A) and (B). The solid line represents
the power of the five tests for Case (A) and the dotted
line for Case (B). The power is plotted with mp, the pro-
portion of the significant genes in each gene set, set to
be 0.0,0.1,0.3 and 0.5. Here mp is considered to be the
effect size because the proportion of significant genes
affects the association between the survival time and the
Table 1 The estimated size of the five tests for p = 200
based on 500 iterations
nmc p GSEA1 GSEA2 GT WT GBST
80 20 0.0 0.058 0.052 0.050 0.050 0.050
0.1 0.060 0.052 0.058 0.058 0.062
0.3 0.034 0.054 0.054 0.066 0.046
0.5 0.062 0.042 0.040 0.032 0.052
50 0.0 0.050 0.048 0.044 0.042 0.052
0.1 0.050 0.056 0.058 0.058 0.036
0.3 0.054 0.040 0.054 0.048 0.052
0.5 0.068 0.060 0.058 0.058 0.060
50 20 0.0 0.054 0.042 0.036 0.032 0.044
0.1 0.062 0.056 0.046 0.046 0.058
0.3 0.056 0.036 0.044 0.038 0.052
0.5 0.046 0.042 0.038 0.046 0.046
50 0.0 0.070 0.046 0.052 0.044 0.046
0.1 0.044 0.048 0.042 0.046 0.038
0.3 0.050 0.038 0.060 0.058 0.060
0.5 0.046 0.046 0.058 0.040 0.050
Note: n = Sample size; m = the size of gene set; cp = censoring proportion.
GSEA1 = GSEA with the equal weight; GSEA2 = weighted GSEA; GT = Global
Test; WT = Wald-type Test; GBST = Global Boost Test
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differs depending on the combinations of the gene cor-
relation structure and the association of genes with sur-
vival. For Case (I), the power of the five tests is higher
for Case (B) than for Case (A). On the other hand, in
the plots for cases (II) and (IV), the power of the five
tests is much higher for Case (A) than for Case (B).
This result implies that there might be a synergistic
effect in the power of detecting significant genes when
the genes are correlated and the survival is positively
associated with genes. For Case (III), the power of GT,
W Ta n dG B S Ti sa l m o s tt h es a m er e g a r d l e s so ft h e
association of genes with survival, whereas both GSEA1
and GSEA2 have higher power for Case (A) than for
Case (B). In general, as described in Figure 1, GT, WT
and GBST consistently have higher power than GSEA1
and GSEA2. Comparing the two GSEA tests, the power
of GSEA2 is equal to or slightly greater than the power
of GSEA1, but these two tests have lower power than
0.5 except for the combinations of cases (II) and (IV)
with Case (A) when mp ≥ 0.3. As shown in Figure 2, the
same pattern of power is found when the censoring
fraction increases from cp = 0.0 to 0.3 though power
consistently decreases as censoring increases.
Analysis of a real example of ovarian cancer data
We next evaluated the performance of the five tests
using an ovarian cancer data set from Dressman et al.
[21]. This dataset consists of 119 ovarian cancer samples
that were obtained at the initial cytoreductive surgery
from patients treated at Duke University Medical Center
and H. Lee Moffitt Cancer Center and Research Insti-
tute. 22115 gene expression levels were used in this ana-
lysis, of which 204 pathways were identified by KEGG.
Among these 204 pathways, the smallest pathway con-
sists of 5 genes while the largest one includes 474 genes,
and the average number of genes across the 204 path-
ways is about 80.
Crijns et al. [22] identified survival-related profile,
pathways and transcription factors by analyzing a data-
set of 157 patients with advanced-stage serious ovarian
cancer from the University Medical Center Groningen
in Netherlands, collected in the time period 1990-2003.
They used the dataset of 119 ovarian cancer samples in
Table 2 The estimated power of the five tests for p = 200, n = 80, and m = 50 based on 200 replications
Case(A) Case (B)
Case cp mp GSEA1 GSEA2 GT WT GBST GSEA1 GSEA2 GT WT GBST
(I) 0.0 0.1 0.145 0.185 0.295 0.275 0.250 0.120 0.185 0.380 0.380 0.345
0.3 0.290 0.370 0.650 0.630 0.635 0.250 0.355 0.750 0.745 0.805
0.5 0.400 0.450 0.825 0.805 0.820 0.400 0.525 0.900 0.905 0.950
0.3 0.1 0.145 0.155 0.155 0.165 0.155 0..65 0.110 0.240 0.270 0.265
0.3 0.245 0.225 0.430 0.420 0.415 0.205 0.230 0.510 0.520 0.540
0.5 0.335 0.330 0.615 0.605 0.620 0.275 0.395 0.725 0.695 0.765
(II) 0.0 0.1 0.165 0.225 0.425 0.485 0.320 0.075 0.135 0.330 0.320 0.295
0.3 0.890 0.965 1.000 1.000 0.980 0.235 0.375 0.755 0.745 0.755
0.5 1.000 1.000 1.000 1.000 1.000 0.430 0.605 0.900 0.890 0.925
0.3 0.1 0.140 0.190 0.310 0.330 0.215 0.100 0.080 0.270 0.285 0.255
0.3 0.730 0.815 0.955 0.970 0.880 0.215 0.295 0.520 0.520 0.570
0.5 0.985 0.995 1.000 1.000 1.000 0.265 0.395 0.670 0.640 0.745
(III) 0.0 0.1 0.120 0.115 0.310 0.335 0.245 0.125 0.135 0.270 0.310 0.280
0.3 0.355 0.460 0.790 0.765 0.735 0.270 0.375 0.745 0.725 0.805
0.5 0.610 0.615 0.895 0.885 0.885 0.385 0.495 0.885 0.890 0.925
0.3 0.1 0.085 0.095 0.215 0.195 0.190 0.070 0.075 0.215 0.220 0.225
0.3 0.260 0.330 0.610 0.585 0.535 0.165 0.275 0.550 0.505 0.595
0.5 0.390 0.445 0.710 0.700 0.725 0.305 0.350 0.735 0.740 0.810
(IV) 0.0 0.1 0.105 0.205 0.440 0.460 0.300 0.100 0.170 0.385 0.415 0.360
0.3 0.815 0.885 0.990 0.990 0.965 0.255 0.340 0.755 0.755 0.760
0.5 0.995 1.000 1.000 1.000 1.000 0.440 0.550 0.875 0.890 0.930
0.3 0.1 0.160 0.215 0.305 0.310 0.265 0.135 0.165 0.240 0.255 0.235
0.3 0.585 0.760 0.925 0.920 0.830 0.185 0.285 0.560 0.550 0.555
0.5 0.960 0.970 1.000 1.000 0.985 0.320 0.410 0.680 0.685 0.760
Note: m = the size of gene set; cp = censoring proportion; mp = the proportion of significant genes in a gene set. GSEA1 = GSEA ith the equal weight; GSEA2 =
weighted GSEA; GT = Global Test; WT = Wald-type Test; GBST = Global Boost Test. For Case (I), all genes are independent; for Case (II), there is within-correlation
among significant genes; for Case (III), there is an autoregressive correlation between significant genes; and for Case (IV), there is an unstructured correlation
between significant genes
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Figure 2 Plots of estimated size and power of the five tests, GSEA1, GSEA2, GT, WT and GBST, over the proportions of significant
genes in each gene-set, using four different correlation structures, two different scenarios for generating the Cox regression
coefficient vector, and censoring level cp = 0.3. The solid and dashed lines correspond to Case (A) that genes are positively associated with
survival time, and to Case (B), that genes are randomly associated with the survival time, respectively. The circle, square, diamond, triangle and
inverted triangle symbols correspond to GSEA1, GSEA2, GT, WT and GBST, respectively.
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Figure 1 The estimated size and power of the five tests, GSEA1, GSEA2, GT, WT and GBST, over the proportions of significant genes
in each gene-set, using four different correlation structures, two different scenarios for generating the Cox regression coefficient
vector, and censoring level cp = 0.0. The solid and the dashed lines correspond to Case (A), that genes are positively associated with the
survival times, and to the Case (B), that genes are randomly associated with the survival time, respectively. The circle, square, diamond, triangle
and inverted triangle symbols correspond to GSEA1, GSEA2, GT, WT and GBST, respectively.
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Page 5 of 10Dressman et al. [21] to validate the identified profile and
pathways.
We compared the pathways identified by the five tests
with those reported in Dressman et al. [21] and Crijns
et al. [22]. In Dressman et al. [21], the significant path-
w a y sw e r ef o u n db yab i n a r yl o g i s t i cr e g r e s s i o nm o d e l
analysis and a stochastic regression model search, called
shotgun stochastic search. On the other hand, Crijns et
al. [22] identified the significant pathways using the
functional class scoring analysis, in which the p-value of
a univariate Cox proportional hazards is computed for
all genes, and then p-values of each pathway are sum-
marized by the mean negative logarithm of single gene
p-values (LS statistic), as well as the Kolmogorov-Smir-
nov (KS) statistic for testing if the p-values come from a
uniform distribution. The significance of each pathway
is evaluated by computing the empirical distribution of
these summary statistics in random samples of genes.
Table 3 displays 19 gene sets with an FDR threshold
of q < 0.1 (Benjamini and Hochberg [23]) based on at
least one of the five tests, along with the corresponding
univariate p-value. The underlined pathways were also
reported to be significant in Dressman et al. [21] and
Crijns et al. [22]. As shown in Table 3, GT, WT and
GBST have greater power to detect significant gene sets
than GSEA1 and GSEA2. For example, GT, WT and
GBST detect 12, 6 and 8 significant pathways among
204 pathways, respectively, while none of pathways is
identified by either GSEA1 or GSEA2. Crijns et al. [22]
listed 17 pathways in their study, of which 16 were con-
firmed by Dressman et al. [21]. Among those, with an
FDR threshold of q < 0.1, three pathways were identified
by at least one of GT, WT and GBST. GT identified all
three pathways - Purine metabolism, Leukocyte transen-
dothelial migration and Jak-STAT signaling - and GBST
identified only one pathway, Leukocyte transendothelial
migration. None of the pathways were identified by WT.
Discussion
Many gene-set analysis proposals have been compared
in simulation studies and on real data sets. However,
most studies have dealt with a binary phenotype like the
presence or absence of disease, or treatment vs. control.
In this paper, we focused on the survival phenotype and
compared five different gene-set analysis tests, GSEA1,
GSEA2, GT, WT and GBST, in a simulation study and
on two ovarian cancer data sets. From the simulation
results, we found that GT, WT, and GBST are more
powerful than GSEA1 and GSEA2. Furthermore, the
power of the five tests is substantially affected by the
Table 3 Pathways with more genes associated with overall survival as identified by either GT or WT at the nominal
0.01 level of the permutation test
Pathway name Gene set size p-value q-value
GSEA1 GSEA2 GT WT GBST GSEA1 GSEA2 GT WT GBST
Pentose phosphate pathway 39 0.010 0.003 0.000 0.000 0.003 0.921 0.612 0.000 0.000 0.087
Histidine metabolism 54 0.070 0.012 0.000 0.000 0.000 0.921 0.638 0.000 0.000 0.000
Tryptophan metabolism 86 0.034 0.024 0.002 0.003 0.009 0.921 0.701 0.061 0.085 0.140
One carbon pool by folate 28 0.065 0.027 0.010 0.000 0.010 0.921 0.701 0.108 0.000 0.140
DNA replication 52 0.021 0.013 0.009 0.002 0.037 0.921 0.638 0.108 0.077 0.207
Colorectal cancer 165 0.139 0.145 0.003 0.010 0.000 0.921 0.811 0.073 0.136 0.000
Nucleotide excision repair 56 0.047 0.068 0.014 0.003 0.054 0.921 0.811 0.129 0.085 0.253
Urea cycle and metabolism of amino groups 40 0.031 0.259 0.010 0.036 0.003 0.921 0.878 0.108 0.191 0.087
Purine metabolism 201 0.081 0.026 0.003 0.009 0.072 0.921 0.701 0.074 0.136 0.275
Aminophosphonate metabolism 21 0.267 0.028 0.000 0.009 0.056 0.921 0.701 0.000 0.136 0.253
Pantothenate and CoA biosynthesis 19 0.252 0.061 0.189 0.010 0.003 0.921 0.811 0.337 0.136 0.087
Leukocyte transendothelial migration 197 0.332 0.161 0.004 0.013 0.003 0.921 0.811 0.074 0.166 0.087
Inositol metabolism 7 0.234 0.274 0.035 0.044 0.004 0.921 0.878 0.207 0.204 0.089
Tyrosine metabolism 81 0.531 0.147 0.017 0.018 0.003 0.970 0.811 0.133 0.171 0.087
Lysine degradation 56 0.124 0.225 0.004 0.018 0.137 0.921 0.878 0.074 0.171 0.362
Starch and sucrose metabolism 72 0.373 0.133 0.002 0.033 0.250 0.928 0.811 0.068 0.191 0.427
Glycerophospholipid metabolism 89 0.535 0.255 0.004 0.028 0.036 0.970 0.878 0.074 0.190 0.207
Androgen and estrogen metabolism 53 0.386 0.168 0.005 0.035 0.147 0.935 0.811 0.085 0.191 0.372
Jak-STAT signaling pathway 240 0.258 0.606 0.001 0.036 0.121 0.921 0.892 0.051 0.191 0.358
Starch and sucrose metabolism 72 0.373 0.133 0.002 0.033 0.250 0.928 0.811 0.068 0.191 0.427
Note: The underlined pathways are identified by Crijns et al.(2009).
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between survival and the genes. The power of the five
tests can approach 1.0 when the genes are correlated,
survival is positively associated with the gene expression
values, and mp ≥ 0.3. For more powerful test results, it
might be desirable to check the correlation structure
among genes within each pathway and the direction of
association between genes and survival.
Although GSEA was originally based on the rank of
the correlation coefficients between a binary phenotype
and gene expression levels, we replaced the correlation
coefficient by the regression coefficient from a Cox
model and took the rank of the absolute value of its
standardized coefficient. We then followed the rest of
the GSEA procedure in order to identify significant
gene-sets or pathways. This is a modification of GSEA
that takes into account the survival phenotype, which
may in some cases be more informative than a binary
phenotype. In addition, the modified GSEA allows cov-
ariance adjustment for age, sex and other clinical vari-
ables by taking the regression coefficient of genes from
the Cox model with those adjusting covariates. However,
the performance of the GSEA tests, GSEA1 and GSEA2,
are not satisfactory except for a few cases. This may be
due to the fact that the GSEA tests are nonparametric
approaches using the rank-based statistic instead of
using the value of the regression coefficient.
On the other hand, GT, WT and GBST have been
proposed for regression-based models and can be
extended to any phenotype such as binary, continuous,
multi-class, or survival. These three tests can be easily
adjusted for covariates, in order to determine whether
gene expression profiles have an association with survi-
val beyond what is explained by the adjusting covariates.
The GT method assumes a random-effect model for the
parameters corresponding to the coefficients of the indi-
vidual genes in the pathway, in which the parameters
are random variables and samples from N(0,τ
2). Here all
parameters are assumed to have a common variance of
τ
2, which can be extended to have a more complex cov-
ariance structure as mentioned in Goeman et al. [6].
T h eG Tm e t h o du s e sas c o r et e s to fτ
2 =0 ,w h i c hi s
equivalent to the null hypothesis that there is no asso-
ciation between survival and a given set of genes. There-
fore, this test does not depend on the number of genes
in a given set and works under the assumption of a ran-
dom-effect model with a common variance. As dis-
cussed in Goeman et al. [6], the score test of GT can
have the optimal power against alternatives with small
values of parameter τ
2. In the simulation study, we gen-
erated the parameter from either a uniform or normal
distribution with small variances. This may have con-
tributed to the high power that we observed for GT. On
the other hand, Boulesteix and Hothorn [8] proposed
the GBST for testing the additional predictive value of
gene expression data while adjusting for clinical covari-
ates. They combined the standard regression models
such as a logistic regression or a Cox model with a
boosting procedure and used a permutation-based test-
ing scheme. While Goeman et al. [5] reduced the multi-
dimensional gene profiles into one-dimensional variance
using a random-effect model, Adewale et al. [9] instead
computed the sum of squares of the Wald statistics for
the genes in the pathway from the univariate regression
model. Likewise, the WT does not depend on the multi-
dimensionality of the gene sets since the test statistic
can be summarized as the sum of individual association
measures. Compared to the GSEA tests, these three
tests are based on parametric approaches since the
values of the regression coefficients are taken into
account in these tests via a score statistic or a sum of
squares.
As pointed out by a referee, methodological issues
should be considered when comparing gene-set analysis
methods. Goeman and Bühlmann [24] addressed the
definition of the null hypothesis, and in particular com-
petitive versus self-contained tests, as well as the calcu-
lation of p-values, and the use of gene sampling versus
subject sampling methods. GT, WT and GBST are
based on the classical statistical models which lead to
test a self-contained null hypothesis. Furthermore, they
calculate the p-value using a subject sampling model.
On the other hand, GSEA is a hybrid method: a Kolmo-
gorov-Smirnov test statistic is motivated by a gene-sam-
pling model, whereas a subject-sampling model is used
to calculate the p-value. It was also pointed out that
GSEA sometimes shows low power since the model and
null hypothesis used to motivate the test statistic are dif-
ferent from the model and null hypothesis used to cal-
culate the p-value. Simulation results indicate that both
GSEA1 and GSEA2 have lower power than GT, WT
and GBST.
One of the important advantages of gene-set analysis
over the single gene approach is that the multiple test-
ing problems can be alleviated because the number of
pathways is much smaller than that of genes. In the
ovarian cancer example, for example, there are 22115
genes. The number of pathways is 204, which is more
than a 100-fold reduction. When a single pathway is of
interest in pathway analysis, the issue of multiple testing
is not a problem. However, when multiple pathways are
of interest, as in cases when pathway analysis is explora-
tory with many pathways of potential interest, then mul-
tiple comparison methods such as false-discovery rates
(FDR) must be applied. In the ovarian cancer example,
we used FDR to control 204 pathway comparisons. A
few pathways were found to have q <0 . 1 .I ti sn o t e d
that all 17 pathways identified by Crijns et al. [22]
Lee et al. BMC Bioinformatics 2011, 12:377
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to 474, and their median is 239. However, GT detects
12 pathways whose sizes range from 39 to 240 with a
median of 79, WT detects 6 pathways whose sizes range
from 28 to 86 with a median of 53, and GBST detects 8
pathways whose sizes range from 7 to 165 with a med-
ian of 47. In summary, GT, WT and GBST detected
pathways with a variety of gene-set sizes, whereas Crijns
et al. [22] detected only large gene sets.
To implement GT and GBST, we adapted the func-
tion ‘gt’ in the R package ‘globaltest’,a n dt h ef u n c t i o n
‘globalboosttest’ in the R package ‘globalboosttest’.W e
implemented GSEA1, GSEA2, and WT from scratch in
R, using the function ‘coxph’. For the readers’ conveni-
ence, all codes are available as additional files. The addi-
tional file 1 is R source codes for generating data,
calling subroutines, and calculating permuted p-values
and the additional file 2 is R source codes for calculat-
ing five test statistics, GSEA1, GSEA2, GT, WT, and
GBST.
Conclusion
In conclusion, GT, WT and GBST have high power to
identify gene sets whose expression is associated with
survival. Survival is often strongly affected by well-
known clinical variables such as stage, type of tumor,
and tumor size, as well as demographic variables such
as age, sex, and race. Therefore, it is very important to
evaluate the effects of genes on survival while consid-
ering known covariates. Since these tests allow for
adjustment for covariates, they assess whether expres-
sion of a given set of genes has an association with
survival after controlling for confounders. In general,
GT, WT and GBST are more powerful than GSEA1
and GSEA2. However, when genes are correlated
within each pathway and survival is positively asso-
ciated with genes, it does not matter which test is
applied to detect significant gene sets, provided that
the number of significant genes is moderately large
within each pathway.
Methods
In this paper, we compared four gene-set analysis
methods, GSEA, Global Test, Wald-type Test and
Global Boost Test, when the phenotype of interest is
survival. These methods involve the test statistic
from a Cox model to predict survival gene expres-
sion. The Cox model assumes that the hazard func-
tion at time t is specified as a function of covariates
as follows:
h(t)=h0(t)exp(β X),
where h0(t) is a baseline hazard function, X =( x1,...,
xp)’ is the p-dimensional covariate vector, and b is a
p × 1 regression coefficient vector relating to gene
expression.
(1) GSEA
Let S be an a priori defined set of genes, out of a total
of p genes in a microarray dataset. GSEA tests the null
hypothesis that the expression of the genes in S is not
associated with a phenotype of interest. The procedure
is as follows:
(i) Compute a correlation or association measure
between each of the p genes and phenotype. Here
we used a t-test statistic, rj = bj/sj, j = 1,..., p,w h e r e
bj is the parameter estimate of the log-hazard ratio,
bj,f o rt h ejth gene’s association with survival, and sj
is its corresponding standard error.
(ii) Order the p genes by the absolute values of rj,
from largest to smallest.
(iii) Compute the Enrichment Score (ES) as follows:
start with ES =0a n ds u mu pf r o mt h et o pr a n k
(j =1 )t ot h el a s tr a n k( j = p), increasing by
| rj|w/
 
k∈S
| rk|w
if the jth gene belongs to the gene
set S, and decreasing by 1/(p-m), otherwise, where w
Î [0,1] and m is the number of genes in the set S.
(iv) Take the maximum deviation from zero of the
ES values among the p genes as the test statistic for
the gene set S.
(v) Randomly permute the survival times and repeat
(i)-(iv) many times.
(vi) Compute the significance level by comparing the
observed value of the test statistic from (iv) to its
permutation distribution obtained from (v).
We considered two different GSEA tests by setting w
= 0,1, respectively. For w = 0, the resulting GSEA test
(GSEA1) is a normalized Kolmogorov-Smirnov statis-
tic, which is the original GSEA proposal of Mootha et
al. [1]. However, it was shown by Subramanian et al.
[ 2 ]t h a tt h eo r i g i n a lG S E Aw i t hw =0m a yh a v eh i g h
ES scores for a set clustered near the middle of the
ranked list, even though such a gene set likely is not
truly associated with the phenotype. To address this
issue, weighting the test statistic according to the cor-
relation between each gene and the phenotype was
proposed by Subramanian et al. [2]. For w =1 ,w ea r e
weighting the genes in S by their correlation with the
p h e n o t y p en o r m a l i z e db yt h es u mo ft h ec o r r e l a t i o n
over all the genes in S. The main idea of the weighted
GSEA (GSEA2) is to allow the magnitude of the
increase in ES to reflect the correlation between the
Lee et al. BMC Bioinformatics 2011, 12:377
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highly a gene is correlated with the phenotype, the lar-
ger the increase in ES that gene is assigned. By com-
paring the performance of GSEA1 and GSEA2, the
effect of weighting on the power can be investigated in
simulation studies.
(2) Global Test
The Global Test is also based on the regression coeffi-
cient from a Cox model. It tests the null hypothesis that
all regression coefficients between survival and gene
expression are zero, as follows:
H0 : β1 = β2 = ···= βm =0 .
We assume that all regression coefficients are random
and sampled from a common distribution with mean
zero and common variance τ
2. Then the null hypothesis
of no differential gene expression is reduced to the
hypothesis that τ
2 = 0. The Global Test is a score test
based on random-effect modeling of parameters corre-
sponding to the coefficients of the individual genes in
the pathway. Goeman et al. [5] originally proposed the
Global Test based on the generalized linear model and
then extended it to survival in the Cox model, in which
a score test was derived for testing the null hypothesis
τ
2 = 0 based on the martingale residual. The test statistic
is given as follows:
Q =
T − ˆ ET
ˆ Var(T)
.
Here, T =( d - û)’ R(d-û) - trace(RÛ) is a function of
the martingale residual, d - û, R = XX’, and Û = diag(û),
where X is a n × m design matrix representing m gene
expressions for n individuals, and û=(û1, û2,..., ûn)’ is
the n × 1 vector of the estimated cumulative hazard
function for the ith individual up to time ti.
(3) Wald-type Test
This test is based on the unified pathway method pro-
posed by Adewale et al. [9], which combines compo-
nent-wise test statistics for significance of a subset of
genes or pathway. The form of the test statistic is a sum
of squares of the Wald statistic for individual genes con-
stituting the pathway, denoted as follows:
W =
m  
j=1
r2
j .
(4) Global Boost Test
This test is a permutation-based testing procedure to
globally assess the additional predictive power of the
expression values of a large number of genes, while
adjusting for a few clinical covariates. Boulesteix and
Hothorn [8] combined two well-known statistical tools,
Cox regression and a boosting algorithm. The procedure
of GBST originally consists of two steps: in the first
step, the effects of clinical variables are estimated and
the corresponding linear predictor is used as an offset in
the second step. However, only intercept was used as an
offset in this simulation study because any clinical vari-
ables were not considered for the comparable result
among five tests. As a result, the procedure of GBST
begins with running the boosting algorithm given in the
section ‘boosting with componentwise linear least
squares’ in Boulesteix and Hothorn [8] using the partial
log-likelihood function. Through the number of boost-
ing iterations, GBST derived the resulting linear predic-
tor as ˆ ηi = ˆ β0 + ˆ β1xi1 + ···+ ˆ βmxim by minimizing the
average negative partial log-likelihood for a Cox model.
Here the partial log-likelihood function is given as fol-
lows:
l(β)=
n  
i=1
δi
⎛
⎝ηi − log
⎛
⎝
n  
j=1
I(tj ≥ ti)exp(ηj)
⎞
⎠
⎞
⎠ ,
where δi is equal to 1 if an event occurred at that time
and 0 if the observation has been censored, and I(·) is an
indicator function taking 1 if its argument is true, i.e., if
individual j is still under risk just before time ti,a n d
value 0 otherwise.
Additional material
Additional file 1: R source codes for generating data, calling
subroutines, and calculating permuted p-values. This is a main
program for generating simulated data sets and calling a subroutine of
calculating test statistics. It also performs to generate the permuted
samples with a given simulated data repeatedly and calculates the
permuted p-value of each test comparing the observed test statistic with
the distribution of the permuted test statistics.
Additional file 2: R source codes for calculating five test statistics,
GSEA1, GSEA2, GT, WT, and GBST. This is a subroutine for calculating
five test statistics included in the article such as GSEA, Global Test, Wald-
type Test, and Global Boost Test.
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